Functionally, SOCS2 silencing reduced the growth of MLL-AF9 transformed murine leukemic cells in vitro and delayed the disease development in a mouse model of MLL-AF9 driven AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.